UBS AM
LCTX icon

UBS AM’s Lineage Cell Therapeutics LCTX Stock Holding History

UBS AM’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-46,519
Closed -$60.9K – 2866
2019
Q1 		$60.9K Buy
46,519
+10,318
+29% +$12.8K ﹤0.01% 2599
2018
Q4 		$33.1K Sell
36,201
-5,177
-13% -$7.93K ﹤0.01% 2603
2018
Q3 		$85.1K Hold
41,378
– – ﹤0.01% 2536
2018
Q2 		$74.6K Hold
41,378
– – ﹤0.01% 2569
2018
Q1 		$97.4K Buy
41,378
+28,575
+223% +$67K ﹤0.01% 2460
2017
Q4 		$24.1K Buy
+12,803
New +$28K ﹤0.01% 2470

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return